BR Ventures announces investment in pharmaceutical technology company
A company whose patent-pending technology holds promise for reducing the cost of making pharmaceutical agents now has the backing of the Johnson School.
BR Ventures, the Johnson School's student-managed venture capital firm, has invested an undisclosed amount in convertible debt in Systanix Inc., based in Lansing, N.Y.
In 2005 Systanix received free start-up help from BR Legal, a Johnson School-based legal services program for new companies, by winning the BR Ventures Business Idea Competition that year. This year's winners will be announced April 20.
BR Ventures is co-investing in Systanix with Excell Partners, a seed-stage venture capital firm that focuses on economic development in upstate New York.
Systanix holds the exclusive license to patent-pending technology that has the potential to reduce the cost of synthesizing pharmaceutical agents and specialty chemicals by 35 percent or more.
The company has developed a chemical synthesis method of combining advanced microreactor design and catalyst technology, a process called SysFlo.
Systanix's approach to chemical synthesis is applicable to the needs of the pharmaceutical, fine chemical and veterinary medicine sectors.
Media Contact
Get Cornell news delivered right to your inbox.
Subscribe